Analysts Expect Venus Medtech (Hangzhou) Inc. (HKG:2500) To Breakeven Soon

Venus Medtech (Hangzhou) Inc. (HKG:2500) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The HK$709m market-cap company announced a latest loss of CN¥408m on 31 December 2025 for its most recent financial year result. Many investors are wondering about the rate at which Venus Medtech (Hangzhou) will turn a profit, with the big question being “when will the company breakeven?” We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

According to some industry analysts covering Venus Medtech (Hangzhou), breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of CN¥2.0m in 2026. The company is therefore projected to breakeven around 12 months from now or less. We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 149% is expected, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving Venus Medtech (Hangzhou)'s growth isn’t the focus of this broad overview, but, bear in mind that typically a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

See our latest analysis for Venus Medtech (Hangzhou)

One thing we’d like to point out is that The company has managed its capital judiciously, with debt making up 9.0% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of Venus Medtech (Hangzhou) which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Venus Medtech (Hangzhou), take a look at Venus Medtech (Hangzhou)'s company page on Simply Wall St. We've also put together a list of relevant aspects you should look at:

1. Historical Track Record: What has Venus Medtech (Hangzhou)'s performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Venus Medtech (Hangzhou)'s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.